fects in reducing oxidative stress in ESRD patients (1, 4) .
Considering low cost, safety, with its beneficial effects, N-acetylcysteine (NAC) has been recommended as a potential anti-inflammatory and antioxidant drug in dialysis patients (5) . NAC is a free radical scavenger that increases glutathione and inhibits inducible nitric oxide synthase, suppresses cytokine expression/release, and inhibits the expression of adhesion molecules (6) (7) (8) . It has been used extensively as a mucolytic agent, in the treatment of acetaminophen toxicity, as a cytoprotective agent during cancer chemotherapy, and in the prevention of contrast-induced nephropathy (9, 10) . Also it is indicated that NAC acts as an adjuvant in the treatment of chronic kidney disease (CKD) anemia (11).
Objectives
In this study, we aimed to evaluate the effects of NAC as an antioxidant on inflammation by measuring highsensitive C-reactive protein (hs-CRP) and on anemia in hemodialysis patients.
Patients and Methods

Patients
In this randomized placebo-controlled clinical trial, 51 ESRD patients on regular hemodialysis 3 times weekly for at least 3 months in Bou-Ali dialysis center, Ardabil were recruited. Patients with vasculitis, cardiac disease, respiratory disorders, uncontrolled diabetes (HbA 1C >7.5%) and those who receiving lipid-lowering agents and immunosuppressive drugs in the last 3 months were excluded from the study. Patients with primary hs-CRP below 6 mg/L, a history of smoking, a known allergy to NAC, chronic inflammatory disease (e.g., rheumatic diseases), evidence of malignancy, cardiac disease or hematologic diseases (e.g., leukemia or lymphoma), active infection, HIV or hepatitis B or C, abnormal liver function tests, use of vitamin E or vitamin C or any antioxidant, were excluded from the study too. Additionally, all study patients were strongly advised to not consume any nutritional material with known anti-oxidant effects. The trial is powered to detect an effect size of d ≥0.70 as statistically significant in a two-tailed test with α = 0.05 and power of 0.80 with N = 25 per condition. As there was possibility that some patients do not complete the study, we included 30 patients in each group. Using RandList 1.2 software, random numbers were produced and according to sample size, patients were enrolled into the study. During the study period, four patients in NAC group (one with infection and three for personal issues) and five patients from placebo group (one died, two with infection and two for personal issues) were lost to follow-up and were excluded (Figure 1 ). 
Intervention and biochemical measurement
For a period of month, patients received NAC 1200 mg daily (intervention group) or placebo (with the similar size, color and shape). Patients and the physician evaluating the treatment outcome were blinded to the regimens. To control the appropriate use of medications, tablets were delivered to the patients weekly and participants gave back the used tablet sheets to be checked. Before and after intervention, blood samples were taken from each patient to measure complete blood cell count, ferritin, hs-CRP, Ca, P and alkaline phosphatase (ALP). The blood samples for measuring all the above-mentioned variables were taken just before the initiation of dialysis.
Ethical considerations
The research followed the tenets of the Declaration of Helsinki; the study protocol was approved by the ethics committee of the Ardabil University of Medical Sciences and all participants gave written informed consent before enrolling into the study. Besides that, the study proto col was registered in the Iranian Registry of Clinical Trials website (identifier: IRCT2016111030821N1; http://www.en.search.irct.ir/view/33908).
Statistical analysis
Results are expressed as mean ± standard deviation (SD) or percentage. The chi-squared and Fisher's exact tests were used to compare categorical variables and the Mann-Whitney U test and independent t test to compare continuous variables. Paired t test was used to compare post treatment results with baseline in each group; P values of less than 0.05 were considered statistically significant. All data were analyzed using SPSS 17 (version 17; SPSS Inc., Chicago, IL).
Results
Fifty-one patients were studied in NAC (n = 26) and placebo (n = 25) group. There was no significant difference between groups regarding baseline findings (Table 1) . Laboratory findings before and after treatment in NAC and placebo group are shown in Table 2 . Among variables, only ferritin levels before and phosphorus levels after treatment were significantly different between groups. Comparing the results before and after treatment in each group, we observed significant changes in hematocrit (P = 0.002), ferritin (P = 0.006), hs-CRP (P = 0.02) and ALP levels (P = 0.005) in NAC group and increase in calcium levels (P < 0.001) in placebo group. In order to better evaluate the efficacy of treatment, we compared the percent of changes in laboratory variables between groups and found only significant difference in calcium changes (Table 2) . No major side-effects were reported following administration of NAC.
Discussion
In this randomized clinical trial, we observed that oral NAC 1200 mg daily for one month can significantly improve ferritin and hs-CRP levels. However, the percentage of changes were not significantly different between NAC and placebo. Previous studies have indicated that oxidative stress may cause systemic inflammation and antioxidant neutralization in hemodialysis patients (1-3). As an antioxidant, the effect of NAC on oxidative stress has been evaluated in different studies (5, (12) (13) (14) (15) . Swarnalatha et al (12) showed that NAC can decrease oxidative stress in hemodialysis patients. Shahbazian et al (13) also reported, NAC administration would reduce oxidative stress in hemodialysis patients. Giannikouris (14) explained that NAC NAC as a supplement therapy may be encouraging in ESRD patients, considering the role of oxidative stress in anemia, inflammation and atherosclerosis in these patients (1) . NAC supplementation shows the capability of inhibiting cytokines and pro-inflammatory biomarker such as hs-CRP. Giannikouris (14) suggested that treating hemodialysis patients with NAC could be associated with restoration of important parameters of antioxidant defense and reduction in the levels of oxidative cellular damage mediators. This is probably due to the ability of NAC as an antioxidant to prevent the activation of NFkB induction and inhibits induction of expression and also secretion of pro-inflammatory cytokines (16) . Also, thiol in NAC inhibited the production pro-inflammation mediators and stimulated GSH cellular system (17) . Oxidative stress on one hand and uremic toxins on the other hand could impair erythropoietin process in ESRD patients. It will increase the destruction of erythrocytes membrane leading to anemia in ESRD patients (18) . In this study we did not observe a significant change in hemoglobin levels following treatment with NAC. Numerus studies recommended that NAC could improve anemia in hemodialysis patients. Swarnalatha et al (12) showed that NAC as an oral supplement may improve the treatment of anemia. Giannikouris (14) also reported higher hemoglobin levels compared to pre-treatment values.
Inhibiting the inflammatory markers and oxidative stress will prevent erythrocytes destruction. In fact, NAC supplementation may preserve membranous RBC reductases, prevent oxidative damage to the RBC membrane, prolong RBC survival, and improve uremic anemia (11) .
The difference between studies could be due to the duration of treatment. We only treated patients for 1 month, but other studies duration were 2 to 3 months, while hemoglobin levels depend on erythropoietic process which needs 120 days. Besides the efficacy of any treatment, its safety is also an issue. Following treatment with NAC we observed no major side effects. Previous studies have also reported very few side effects (11).
Conclusions
One month treatment with oral NAC resulted in reduced levels of hematocrit, ferritin and hs-CRP, indicative of role of NAC in controlling inflammation in ESRD patients under hemodialysis. However, NAC was not effective in treatment of anemia, although the treatment duration was low.
Study limitations
Our study is subject to limitations, such as the relatively small sample of patients and short duration of treatment. Also, in this trial, we did not measure biomarkers of oxidative stress.
